Low to moderate pains (headache, muscle and joint pain, and others). Fever in the course of colds, viral infections and other diseases.
Composition:
1 tabl Effervescent contains 500 mg of Acetylsalicylic acid and 200 mg of ascorbic acid. The drug contains sodium (356 mg / 1 tablet).
Action:
Acetylsalicylic acid works mainly by inhibiting the synthesis of prostaglandins (prostaglandins E2, I2 and thromboxane A2) due to the inhibition of arachidonic acid cyclooxygenase. It also inhibits platelet aggregation. Has analgesic, antipyretic and anti-inflammatory effects. Ascorbic acid affects tissue respiration and is necessary in the processes of changes taking place in the body. Ascorbic acid is reversibly oxidized to dehydroascorbic acid. Both compounds are very important in oxidation-reducing processes in the body. In the period of illness and recovery, the demand for ascorbic acid increases. Acetylsalicylic acid from the digestive tract is absorbed in 80-100%. The rate of absorption of soluble forms is greater than that of conventional forms. Ascorbic acid is easily absorbed after oral administration. In plasma, acetylsalicylic acid is hydrolyzed to salicylic acid, which is rapidly distributed throughout the body. Salicylic acid is coupled in the liver to salicylic acid, phenol and acyl glucuronate and to other metabolites. It is excreted in the urine: 1% of an oral dose in a non-hydrolyzed form, the remainder in the form of salicylic acid and its metabolites. T0,5 acetylsalicylic acid is 2-3 h, and salicylic acid is about 6 h. Ascorbic acid is metabolized to inactive compounds excreted in the urine.
Contraindications:
Hypersensitivity to the components of the drug. Hypersensitivity to other NSAIDs, with symptoms such as: bronchospasm, hay fever, shock. Bronchial asthma, chronic respiratory diseases, hay fever or nasal mucosa edema. Active peptic ulcer of the stomach and / or duodenum and inflammation or bleeding from the gastrointestinal tract. Severe hepatic and / or renal failure. Severe heart failure. Blood coagulation disorders (eg haemophilia, thrombocytopenia) and concomitant treatment with anticoagulants (eg coumarin derivatives, heparin). Glucose-6-phosphate dehydrogenase deficiency. Co-administration with Methotrexate at doses of 15 mg / week or more due to myelotoxicity. Use in children under 12 years of age, especially in the course of viral infections (eg chickenpox, influenza), due to the risk of Reye's syndrome. III trimester of pregnancy and breastfeeding.
Precautions:
Caution should be used in patients with renal impairment, chronic renal failure; with juvenile rheumatoid arthritis and / or systemic lupus erythematosus, impaired hepatic function (liver function monitoring), and also with genital haemorrhage, excessive menstrual bleeding, use of contraceptive intrauterine device, hypertension, heart failure and in elderly patients century. Caution should be exercised when co-administering acetylsalicylic acid with methotrexate at doses lower than 15 mg / week, due to increased methotrexate toxicity on the bone marrow. Acetylsalicylic acid should be discontinued 5-7 days before the planned surgery, due to the risk of prolonged bleeding time. It must not be used in patients who are taking oral anti-diabetic medicines from the sulphonylurea group (risk of increased hypoglycaemic effect) and in patients taking anti-gout medicines. Do not drink alcohol while using the drug. The medicine contains sodium (356 mg / 1 tablet), which should be taken into account in patients who control sodium content in the diet.
Pregnancy and lactation:
In the I and II trimester of pregnancy, the drug can only be used if it is absolutely necessary to use the lowest effective dose for the shortest possible time. The drug is contraindicated in the third trimester of pregnancy.In the third trimester of pregnancy, all prostaglandin synthesis inhibitors may affect the fetus on the cardiovascular system (pulmonary hypertension with premature closure of the Botalla ductus arteriosus) and on the kidneys (renal failure with oligohydramnios) and in the mother and newborn result in prolonged bleeding time and inhibit uterine contractility. The drug is contraindicated during breastfeeding. Cyclooxygenase-inhibiting drugs can cause fertility disturbances in women by affecting ovulation; this effect is transient and disappears after completion of therapy.
Side effects:
During treatment, indigestion, heartburn, feeling of fullness in the epigastrium, nausea, vomiting, lack of appetite, abdominal pain, gastrointestinal bleeding, damage to the gastric mucosa, ulcer disease, perforations; focal liver cell necrosis, tenderness and hepatomegaly (especially in patients with juvenile rheumatoid arthritis, systemic lupus erythematosus, rheumatic fever or a history of liver disease), transient increase in serum transaminases, alkaline phosphatase and bilirubin; tinnitus, impaired hearing, dizziness, fatigue, burning sensation behind the sternum, insomnia, drowsiness; proteinuria, presence of leucocytes and erythrocytes in the urine, renal papillary necrosis, interstitial nephritis; heart failure; hypertension, redness of the face; thrombocytopenia, anemia due to gastrointestinal bleeding, haemolytic anemia in patients with G-6-PD deficiency, leukopenia, agranulocytosis, eosinopenia, increased risk of bleeding, prolonged bleeding time, prolonged bleeding time, prolonged prothrombin time; rash, urticaria, angioneurotic edema, bronchospasm, shock.
Dosage:
Orally. Adults: 1-2 tabl. once, if necessary, the dose can be repeated 2-3 times a day. The maximum daily dose of acetylsalicylic acid is 3 g. Youth> 12 years: 1-2 tabl. per day. Do not use for more than 3 days. The drug should be taken during a meal; the tablet should be dissolved in 3/4 glass of water.
(C)
